That's a great post you did last year Chris and worth resurrecting to show the behaviour they displayed during 2018/19. Endless excuses as well as blaming HC keyboard warriors, taking offence at the ASX asking more questions than they felt were warranted, and this little nugget to further support the extended suspension...."1st August 2018 - CGB Suspended due to "failure to lodge the quarterly report for the quarter ended 30 June 2018 by the due date"
They were already suspended anyway from the day prior and now this time around they've failed yet again to lodge the March quarterly, as well as the 6-monthly to end Dec 2022.
So, imo, even if they resolve this acquisition farce, they still have to remain suspended under the Reporting Regs (as was the case in Aug '18) which is a kinda 'backup' for them in freezing shareholders' funds.
In the meantime, it's coming up on the 12mth anniversary (8th July) when Medcan initiated proceedings against CGB for non-payment under their contract - still no resolution, nor any date scheduled for another day in Court including still retaining external legal advisors (unnecessarily imo) to stand in their defence. Great way to 'preserve shareholder funds' eh...
Anyway, Chris' link above is well worth a refresher to jog the memory back to a slightly comparative period in time insofaras a riduculous lenghty suspension is concerned.
Glah, AE
CGB Price at posting:
2.1¢ Sentiment: Hold Disclosure: Held